Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY 54.84
-0.54 (-0.98%)
Apr 28, 2026, 3:00 PM CST
SHA:600276 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 28,948 | 28,013 | 25,010 | 22,377 | 21,213 | 25,780 |
Other Revenue | 3,616 | 3,616 | 2,975 | 442.6 | 62.25 | 125.22 |
| 32,564 | 31,629 | 27,985 | 22,820 | 21,275 | 25,906 | |
Revenue Growth (YoY) | 11.55% | 13.02% | 22.63% | 7.26% | -17.87% | -6.59% |
Cost of Revenue | 4,472 | 4,450 | 3,881 | 3,562 | 3,503 | 3,756 |
Gross Profit | 28,093 | 27,180 | 24,104 | 19,257 | 17,772 | 22,150 |
Selling, General & Admin | 12,174 | 11,913 | 10,892 | 9,994 | 9,654 | 12,244 |
Research & Development | 7,079 | 6,961 | 6,583 | 4,954 | 4,887 | 5,943 |
Other Operating Expenses | 173.3 | 200.79 | 182.17 | 149.03 | 145.32 | 201.81 |
Operating Expenses | 19,462 | 19,094 | 17,628 | 15,081 | 14,712 | 18,385 |
Operating Income | 8,630 | 8,086 | 6,476 | 4,176 | 3,060 | 3,765 |
Interest Expense | -3.87 | -14.35 | -5.56 | -5.9 | -6.49 | -4.71 |
Interest & Investment Income | 1,031 | 785.39 | 607.56 | 477.14 | 772.64 | 580.9 |
Currency Exchange Gain (Loss) | -363.38 | -363.38 | -24.04 | 7.9 | 93.19 | -22.42 |
Other Non Operating Income (Expenses) | -354.72 | -5.57 | -0.61 | 0.74 | -1.37 | -198.97 |
EBT Excluding Unusual Items | 8,940 | 8,488 | 7,053 | 4,656 | 3,918 | 4,119 |
Gain (Loss) on Sale of Investments | 181.03 | 93.39 | 108.63 | -107.41 | 76.5 | 36.23 |
Gain (Loss) on Sale of Assets | 6.45 | 4.05 | 5.4 | 3.16 | 4.23 | 1.64 |
Asset Writedown | -16.21 | -3.29 | -4.94 | -76.21 | -130 | - |
Other Unusual Items | 77.89 | 125.15 | 7.55 | 191.68 | 100.11 | 309.04 |
Pretax Income | 9,189 | 8,708 | 7,170 | 4,667 | 3,968 | 4,466 |
Income Tax Expense | 1,067 | 990.62 | 832.7 | 389.29 | 153.35 | -17.72 |
Earnings From Continuing Operations | 8,122 | 7,717 | 6,337 | 4,278 | 3,815 | 4,484 |
Minority Interest in Earnings | -2.29 | -5.95 | -0.47 | 24.62 | 91.23 | 46.19 |
Net Income | 8,119 | 7,711 | 6,337 | 4,302 | 3,906 | 4,530 |
Net Income to Common | 8,119 | 7,711 | 6,337 | 4,302 | 3,906 | 4,530 |
Net Income Growth | 18.67% | 21.69% | 47.28% | 10.14% | -13.77% | -28.41% |
Shares Outstanding (Basic) | - | 6,480 | 6,337 | 6,327 | 6,404 | 6,381 |
Shares Outstanding (Diluted) | - | 6,535 | 6,337 | 6,327 | 6,404 | 6,381 |
Shares Change (YoY) | - | 3.13% | 0.15% | -1.20% | 0.36% | -0.18% |
EPS (Basic) | - | 1.19 | 1.00 | 0.68 | 0.61 | 0.71 |
EPS (Diluted) | - | 1.18 | 1.00 | 0.68 | 0.61 | 0.71 |
EPS Growth | - | 18.00% | 47.06% | 11.47% | -14.09% | -28.28% |
Free Cash Flow | 8,502 | 8,273 | 5,454 | 6,160 | -726.91 | 2,554 |
Free Cash Flow Per Share | - | 1.27 | 0.86 | 0.97 | -0.11 | 0.40 |
Dividend Per Share | 0.200 | 0.200 | 0.200 | 0.200 | 0.160 | 0.160 |
Dividend Growth | - | - | - | 25.00% | - | -4.02% |
Gross Margin | 86.27% | 85.93% | 86.13% | 84.39% | 83.53% | 85.50% |
Operating Margin | 26.50% | 25.57% | 23.14% | 18.30% | 14.38% | 14.53% |
Profit Margin | 24.93% | 24.38% | 22.64% | 18.85% | 18.36% | 17.49% |
Free Cash Flow Margin | 26.11% | 26.16% | 19.49% | 26.99% | -3.42% | 9.86% |
EBITDA | 9,453 | 8,889 | 7,198 | 4,843 | 3,599 | 4,260 |
EBITDA Margin | 29.03% | 28.10% | 25.72% | 21.22% | 16.91% | 16.45% |
D&A For EBITDA | 822.43 | 802.4 | 722.29 | 666.52 | 539.12 | 495.59 |
EBIT | 8,630 | 8,086 | 6,476 | 4,176 | 3,060 | 3,765 |
EBIT Margin | 26.50% | 25.57% | 23.14% | 18.30% | 14.38% | 14.53% |
Effective Tax Rate | 11.62% | 11.38% | 11.61% | 8.34% | 3.86% | - |
Revenue as Reported | 32,564 | 31,629 | 27,985 | 22,820 | 21,275 | 25,906 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.